R Squared’s Lexaria Bioscience LEXX Stock Holding History

R Squared’s Portfolio LEXX Stock Details LEXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,620	Closed	-$5.5K	–	942
2024 Q4	$5.5K	Buy	+2,620	New	+$6.45K	0.01%	1298

Other funds holding LEXX

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

BAM

Byrne Asset Management Kingston, New Jersey $185M AUM 41.05% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

R Squared's LEXX Position: Q1 2025 in Review

R Squared sold out of Lexaria Bioscience (LEXX) in Q1 2025, closing a stake of 2,620 shares — an estimated $5.5K sold.

R Squared first reported a position in LEXX in Q4 2024 and held it in 1 quarter. The position peaked at $5.5K in Q4 2024. 22 funds tracked by Wall St. Rank hold LEXX as of Q1 2025.

R Squared reported no remaining Lexaria Bioscience position as of Q1 2025 after selling out during the quarter.
R Squared sold 2,620 Lexaria Bioscience shares in Q1 2025, an estimated $5.5K.
R Squared first reported a position in Lexaria Bioscience in Q4 2024 and held it in 1 quarter.
R Squared's Lexaria Bioscience position peaked at $5.5K in Q4 2024.
22 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.